Actively Recruiting
Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
Led by Hospital Israelita Albert Einstein · Updated on 2024-07-17
80
Participants Needed
3
Research Sites
124 weeks
Total Duration
On this page
Sponsors
H
Hospital Israelita Albert Einstein
Lead Sponsor
M
Ministry of Health, Brazil
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus in Brazil. The expectation is to include at least 80 patients over six months, with a follow-up of 90 days from inclusion, through contact via decentralized visits.
CONDITIONS
Official Title
Observational, Prospective, Cohort Study of Mpox Infection in Brazil (NETPOX)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged 65 18 years with confirmed MPOX infection by PCR, culture, or antigen test from blood, oropharynx, anal or skin lesion sample collected within 4 days of enrollment
You will not qualify if you...
- Unable to provide informed consent
- Judged by the study team as unable to participate in decentralized follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Hospital Universitário João de Barros Barreto
Belém, Pará, Brazil
Actively Recruiting
2
Hospital Israelita Albert Einstein
São Paulo, São Paulo, Brazil
Actively Recruiting
3
Hospital Naval Marcílio Dias
Rio de Janeiro, Brazil
Actively Recruiting
Research Team
H
Henrique AR Fonseca, PhD
CONTACT
D
Diogo Moia, PharmD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here